DZD Announces Positive Data from Multiple Studies Demonstrating Promise of New Technology
October 21 2020

Initial results show new class of diagnostics can provide culture-free pathogen identification and drug-resistance profile within hours, not days

Read More
Day Zero Diagnostics Moves Headquarters to SmartLabs at Boston Landing
August 3 2020

Company now occupies over 9,000 square feet of cutting-edge office and lab space

Read More
Day Zero Diagnostics
DZD Research Highlighted in Two Publications on Plasmid-Mediated Antibiotic Resistance
June 2 2020

DZD technical expertise enables identification of novel mechanisms of antibiotic resistance using nanopore sequencing

Read More
DZD Awarded $6.2M Non-Dilutive Funding to Develop Rapid Antibiotic Resistance Diagnostic
May 11 2020

CARB-X selects Day Zero Diagnostics for their global portfolio of technologies to combat antibiotic-resistance

Read More
EpiXact® Helps Stop a Carbapenem-Resistant Acinetobacter baumannii Outbreak in a Burn ICU
February 28 2020

Research published in Infection Control and Hospital Epidemiology details use of patient and environmental whole genome sequencing to stop a CRAB outbreak

Read More
EpiXact® Used to Identify Drug-Resistant E. coli Transmitted by Fecal Microbiota Transplant
November 6 2019

EpiXact confirms cause of first patient death reported from an FMT procedure in research published in the New England Journal of Medicine

Read More